Clinical trial · Observational
A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)
NCT05652712CI-TRIAL-00062701unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our project is going to clarify the efficacy and safety of Toripalimab in lung cancer in the real world, and to evaluate the incidence of adverse events (AEs) of special interest during Toripalimab immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Toripalimab | Drug | Toripalimab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Immunotherapy Regimen
- description
- Patients receiving different treatment regimens of Toripalimab in each center were consecutively enrolled from January 1, 2019 to December 31, 2022
- interventionNames
- Drug: Toripalimab
Primary outcomes (1)
- measure
- Overall survival(OS)
- timeFrame
- 2 years
- description
- OS was calculated from the date of randomization to death from any cause.
Secondary outcomes (4)
- measure
- Progression Free Survival(PFS)
- timeFrame
- 2 years
- description
- PFS was defined as the time from the first day of study treatment to the first documented disease progression per irRC or death due to any cause, whichever occurred first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Cytologically or histologically confirmed lung cancer. * Complete clinical data. * Indications for immunotherapy with Toripalimab. Exclusion Criteria: * Lack of patient key data. * Refusal or uncooperation with the study.
References
Publications (0)
Data not yet available
No reference posted for this study.